A Study of HQP1351 in Patients With GIST or Other Solid Tumors

Official title

A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Oral HQP1351 in Patients With GIST or Other Solid Tumors.

Overview

This study is a Multi-center, Open-label Phase 1 Study to Determine the Recommend Phase 2 Dose (RP2D) and Evaluate PK/PD and preliminary Efficacy of HQP1351 in Patients With GIST or Other Solid Tumors.

Detailed description

The primary objective of this phase 1 study is to determine the RP2D of HQP1351 in patients with GIST or other solid tumors. The secondary objective is to assess the safety, tolerability, PK and preliminary anti-tumor activities of HQP1351 in Patients With GIST or Other Solid Tumors.

Interventions

• Drug HQP1351
  HQP1351 Orally, once every other day (QOD) for consecutive 4 weeks each cycle.

Primary outcome measures

• Safety and tolerance [Time frame: 30 days after the last dose of HQP1351]

Secondary outcome measures (3)

• Maximum plasma concentration (Cmax) of HQP1351 on Day 1 and Day 27 post HQP1351 treatment on cycle 1. [Time frame: 28 days]
• Area under the plasma concentration versus time curve (AUC) of HQP1351 on Day 1 and Day 27 post HQP1351 treatment on cycle 1. [Time frame: 28 days]
• Anti-tumor activities of HQP1351 [Time frame: 3-60 months]

Eligibility criteria

Inclusion criteria

• Male or not pregnant or lactating women, age≥12years.
• Advanced and/or metastatic GIST or other solid tumors, confirmed by histology and/or cytology. GIST patients must be primary resistant to imatinib (tumor progresses within 6 months first-line imatinib treatment, or succinate dehydrogenase B (SDHB) deficient confirmed by immunohistochemistry, or NF1 mutation), OR imatinib or imatinib and at least one other TKI treatment failure (after imatinib or other TKI treatment for more than 6 months, tumor progress again after achieving tumor remission or stability).
• ECOG≤ 2.
• Estimated survival at least 3 months.
• Adequate hematologic and bone marrow functions.
• Adequate renal and liver function.
• Heart function index:

• Troponin(I/T) ≤ Upper Limit of Normal;
• Ejection fraction >40%;
• QTc interval ≤ 450 ms in male or ≤ 470 ms in female.
• Negative serum pregnancy test (for women of childbearing potential) documented within the 24-hour prior to the first dose of investigational product.
• Willing to use contraception by a method that is deemed effective by the investigator by Subject and their partners throughout the treatment period and for at least 30 days following the last dose of study drug.
• Ability to understand and willingness to sign a written informed consent form (the consent form must be signed by the subject prior to any study-specific procedures).
• Willing and ability to comply with study procedures and follow-up examination.

Exclusion criteria

• Received any anti-cancer chemotherapy, biological agent treatment (e.g. Monoclonal antibody), immunotherapy (e.g. IFN) or radiotherapy with 28 days or 5 times half- time before first dose of HQP1351.
• Received any TKIs within 14 days before first dose of HQP1351.
• Attended any clinical trials on other drugs within 14 days before first dose of HQP1351.
• Have not recovered (> Grade 1 by CTCAE, v. 4.0) from AEs (except alopecia) due to agents previously administered.
• Malabsorption syndrome or other diseases that affect the absorption of oral drugs.
• Cardiovascular diseases of clinical significance, uncontrollable or active, including but not limited to: history of myocardial infarction; unstable history of angina pectoris; a history of congestive heart failure or lower left ventricular ejection fraction (LVEF) than normal limit within 6 months; the history of atrial arrhythmias was judged by the researchers to have important clinical significance; history of ventricular arrhythmias, etc.
• Hypertension was still poorly controlled after medication treatment (SBP > 140 mmHg and/or DBP > 90 mmHg).
• Concurrent use any medication led to prolong QT interval.
• Pulmonary mean arterial pressure>35 mmHg by ECHO.
• Significant severe cardiovascular conditions during previous TKI treatment.
• Uncontrollable hypertriglyceridemia.
• Performed major surgery (except for intravenous catheterization or bone marrow biopsy) within 14 days of first dose of HQP1351.
• Arterial thrombosis or embolism events such as cerebrovascular accident (including transient ischemic attack, TIA), or venous thrombosis events or pulmonary embolism within 6 months before the first dose of HQP1351 or deep vein thrombosis within 3 months before the first dose of HQP1351.
• Brain metastasis.
• Had other primary malignant tumors in the last three years (exception of the tumors being cured for 5 years or more, or complete removal of non-melanoma skin cancer or successful treatment of carcinoma in situ, or the controlled prostate cancer).
• Had active, symptomatic infections (including known infections of HIV, viral hepatitis (A, B, or C)). If there is no history of infection, screening is not required.
• Subjects who are known to be allergic to pharmaceutical ingredients or their analogs.
• Pregnancy or lactation, or expect to be pregnant during the study period.
• According to the judgment of the investigator or sponsor, any symptoms or disease of the subject may jeopardize the safety or safety assessment of the subject.
• Any other condition or circumstance of that would, in the opinion of the investigator, make the patient unsuitable for participation in the study.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Open label

Primary purpose

Treatment

Study locations

China · 6 centers

• Sun-Yat Sen University Cancer Center — Guangzhou
• Guangdong general hospital — Guangzhou
• Henan cancer hospital — Zhengzhou
• Union Hospital Tongji Medical College of Huazhong University of Science ang Technology — Wuhan
• Chinese PLA general hospital, Beijing, China — Beijing
• Fudan University Shanghai Cancer Center — Shanghai

Publications

• Qiu HB, Liang Z, Yang J, Zhou Y, Zhou ZW, Wan XB, Li N, Tao KX, Li Y, Wu X, Yang C, Chen Z, Wang H, Men L, Xiong Y, Liu L, Yang D, Zhai Y, Xu RH. Olverembatinib, a multikinase inhibitor that modulates lipid metabolism, in advanced succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 1b study and translational research. Signal Transduct Target Ther. 2025 Nov 4;10(1):361. doi: PMID 41184234

Identifiers

NCT: NCT03594422 · SJ-0003

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗